Association Review
In brief The association between CYP2C9 (Cytochrome P450 Family 2 Subfamily C Member 9) and Major Depressive Disorder is reported, with clinical genetic testing available.
Sources
1
Clinical variants
0
Symptoms
3
Compounds
24
Trials
496 of 4,403 via CYP2C9 compounds
Publications
0
Contents
01
At a glance
Association overview A cited synthesis of the gene–disorder association, with a clinical-actionability summary where the evidence supports one.
Request access 02
Provenance
Evidence and sources 1 source
Every contributing database and publication behind this association, with evidence type, strength, accessions and deep links.
Request access 1 source summary
A gene summary alongside the source descriptions it was distilled from.
Request access 04
Major Depressive Disorder
The disorder 14 database identifiers
The disorder’s summary, prevalence, aliases and cross-reference identifiers (OMIM, Orphanet, MONDO, ICD-10, MedGen).
Request access 05
Phenotype
Clinical features 1 clinical feature
The disorder’s clinical features (HPO) grouped by body system, each with observed frequency and penetrance.
Request access 06
Population genetics
GWAS signals 1 GWAS phenotype
Gene-associated GWAS phenotypes matching the disorder, with best SNP, score, risk-allele frequency and effect size.
Request access 07
Interventions
Therapeutics 24 compounds & drugs
Gene-targeting drugs and associated compounds, with class, approval status, mechanism, indications and trials.
Request access 08
Human studies
Clinical trials 4,403 clinical trials
Clinical trials reached through the pair’s compounds, keeping disorder-targeting trials separate from other indications.
Request access 09
Provenance
References & sources 7 references
Every source and publication cited across this dossier, as one numbered reference list.
Request access 
